Moxiquest 18.92 mg/g Oral Gel for Horses & Ponies

국가: 영국

언어: 영어

출처: VMD (Veterinary Medicines Directorate)

유효 성분:

Moxidectin

제공처:

Zoetis UK Limited

ATC 코드:

QP54AB02

INN (International Name):

Moxidectin

약제 형태:

Oral gel

처방전 유형:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

치료 그룹:

Horses

치료 영역:

Endectocide

승인 상태:

Expired

승인 날짜:

2012-07-18

제품 특성 요약

Revised: June 2014
AN: 01740/2013
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Moxiquest 18.92 mg/g Oral Gel for Horses & Ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 g contains:
ACTIVE SUBSTANCE:
Moxidectin
18.92 mg
EXCIPIENTS:
Benzyl alcohol
37.84 mg
Disodium Edetate
0.24 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral gel
Yellow gel
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Horses and ponies.
4.2.
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The veterinary medicinal product is indicated for treatment of
infections caused
by moxidectin sensitive strains of:
Large strongyles:

_Strongylus vulgaris_ (adults and arterial stages)

_Strongylus edentatus_ (adults and visceral stages)

_Triodontophorus brevicauda_ (adults)

_Triodontophorus serratus_ (adults)

_Triodontophorus tenuicollis _ (adults)
Small strongyles (adults and intraluminal larval stages):

_Cyathostomum _spp.

_Cylicocyclus _spp_._

_Cylicostephanus _spp_._

_Cylicodontophorus_ spp.

_Gyalocephalus _spp.
Ascarids:

_Parascaris equorum_ (adult and larval stages)
Revised: June 2014
AN: 01740/2013
Page 2 of 5
Other species:

_Oxyuris equi _(adult and larval stages)

_Habronema muscae _(adults)

_Gasterophilus intestinalis _(L2, L3)

_Gasterophilus nasalis _(L2, L3)

_Strongyloides westeri _(adults)

_Trichostrongylus axei_
The veterinary medicinal product has a persistent efficacy of two
weeks against
small strongyles. The excretion of small strongyles eggs is suppressed
for 90
days.
The veterinary medicinal product is effective against (developing)
intramucosal
L4 stages of small strongyles. At 8 weeks after treatment, early
(hypobiotic) EL3
stages of small strongyles are eliminated.
4.3.
CONTRAINDICATIONS
Do not administer to young foals less than 4 months.
Do not administer in cases of known hypersensitivity to the active
ingredient or
to any other milbemycins and to any other ingredients of the
veterina